We are live on ! Find out more
BSX icon

Boston Scientific

788 hedge funds and large institutions have $49B invested in Boston Scientific in 2019 Q1 according to their latest regulatory filings, with 115 funds opening new positions, 301 increasing their positions, 248 reducing their positions, and 51 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more first-time investments, than exits

New positions opened: 115 | Existing positions closed: 51

121% more call options, than puts

Call options by funds: $143M | Put options by funds: $64.6M

21% more repeat investments, than reductions

Existing positions increased: 301 | Existing positions reduced: 248

9% more capital invested

Capital invested by funds: $44.9B → $49B (+$4.1B)

8% more funds holding

Funds holding: 730788 (+58)

0.3% less ownership

Funds ownership: 92.18%91.89% (-0.3%)

25% less funds holding in top 10

Funds holding in top 10: 2015 (-5)

Holders
788
Holders Change
+58
Holders Change %
+7.95%
% of All Funds
17.06%
Holding in Top 10
15
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-25%
% of All Funds
0.32%
New
115
Increased
301
Reduced
248
Closed
51
Calls
$143M
Puts
$64.6M
Net Calls
+$78M
Net Calls Change
-$12M
Name Holding Trade Value Shares
Change
Change in
Stake
Legal & General Group
26
Legal & General Group
United Kingdom
$329M +$59.9M +1,567,394 +22%
Aberdeen Group
27
Aberdeen Group
United Kingdom
$296M -$61.2M -1,601,460 -17%
AllianceBernstein
28
AllianceBernstein
Tennessee
$272M -$22.1M -579,444 -8%
Morgan Stanley
29
Morgan Stanley
New York
$264M -$30.2M -791,002 -10%
TCIM
30
TIAA CREF Investment Management
New York
$263M +$24.5M +640,207 +10%
VOYA Investment Management
31
VOYA Investment Management
Georgia
$252M -$2.45M -64,195 -1%
Deutsche Bank
32
Deutsche Bank
Germany
$247M +$115M +3,015,719 +88%
Capital Research Global Investors
33
Capital Research Global Investors
California
$245M -$383M -10,015,149 -61%
DZ Bank
34
DZ Bank
Germany
$225M +$116M +3,028,077 +107%
O
35
OrbiMed
New York
$222M
O
36
OppenheimerFunds
New York
$217M -$17.6M -462,003 -8%
Charles Schwab
37
Charles Schwab
California
$212M +$3.1M +81,194 +1%
Neuberger Berman Group
38
Neuberger Berman Group
New York
$209M -$18.7M -490,866 -8%
Sumitomo Mitsui Trust Group
39
Sumitomo Mitsui Trust Group
Japan
$207M -$2.1M -54,997 -1%
Swiss National Bank
40
Swiss National Bank
Switzerland
$199M +$435K +11,400 +0.2%
PI
41
Putnam Investments
Massachusetts
$193M -$7.54M -197,334 -4%
SIG
42
Senator Investment Group
New York
$192M -$19.1M -500,000 -9%
TP
43
Third Point
New York
$192M +$191M +5,000,000 New
Millennium Management
44
Millennium Management
New York
$179M -$820K -21,458 -0.5%
A
45
AustralianSuper
Australia
$177M +$176M +4,620,692 New
EIP
46
Epoch Investment Partners
New York
$170M -$5.58M -146,035 -3%
Marshall Wace
47
Marshall Wace
United Kingdom
$169M +$121M +3,158,088 +251%
American Century Companies
48
American Century Companies
Missouri
$169M +$10.1M +265,691 +6%
UBS AM
49
UBS AM
Illinois
$165M +$145K +3,789 +0.1%
Bessemer Group
50
Bessemer Group
New Jersey
$163M +$162M +4,244,722 +105,695%

BSX Hedge Fund Activity: Q1 2019 in Review

788 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Boston Scientific (BSX) for Q1 2019, worth a combined $49B — up 9.1% from $44.9B a quarter earlier.

Buyers outnumbered sellers: 115 funds opened new BSX positions and 51 closed out — a net gain of 64 holders — while 301 added to existing stakes and 248 trimmed.

The largest buyer was Third Point, opening a new position worth an estimated $191M. The largest seller was Capital Research Global Investors, cutting an estimated $383M.

  • 788 institutional investors held Boston Scientific (BSX) as of Q1 2019, up from 730 in Q4 2018.
  • Funds reported $49B of Boston Scientific stock for Q1 2019, up 9.1% quarter-over-quarter.
  • 115 funds opened new Boston Scientific positions in Q1 2019 and 51 closed out, a net change of +64 holders.
  • The largest Boston Scientific buyer in Q1 2019 was Third Point, an estimated $191M added.
  • The largest Boston Scientific seller in Q1 2019 was Capital Research Global Investors, an estimated $383M sold.

Based on aggregated 13F filings for Q1 2019.